Write a notes on Remi fentanyl pca in labour analagesia

Reading File

Finding Sources

Searching PubMed

remifentanil patient-controlled analgesia labour

Reading File

Finding Sources

Reading Article

Finding Sources

Searching the Web

remifentanil PCA labour analgesia protocol dosing side effects monitoring 2023 2024

Reading File

Finding Sources

Reading Web Page

remifentanil PCA dosing protocol side effects monitoring labour analgesia

Reading File

I now have comprehensive information from textbooks, PubMed meta-analyses, and clinical guidelines. Let me compile the detailed notes.

Remifentanil PCA in Labour Analgesia

1. Introduction

Remifentanil is a synthetic ultra-short-acting µ-opioid receptor agonist with unique pharmacokinetic properties that make it particularly attractive for use in labour. Its patient-controlled analgesia (PCA) application has grown significantly as an alternative for women in whom neuraxial analgesia is contraindicated, refused, or technically not feasible. Its use remains off-label in most countries, mandating informed consent.

2. Pharmacological Basis

Property	Detail
Drug class	Phenylpiperidine µ-opioid agonist
Onset	~60–90 seconds
Peak effect	~60–90 seconds
Duration	3–5 minutes
Metabolism	Ester hydrolysis by non-specific blood and tissue esterases (not hepatic)
Context-sensitive half-time	Remarkably short (~3 min, regardless of infusion duration)
Placental transfer	Crosses placenta readily but rapidly metabolised in neonate

The ultrashort action is ideally matched to the cyclical nature of uterine contractions, which typically occur every 2–5 minutes. When timed correctly, the bolus produces peak analgesia during the contraction and dissipates before the next — minimising cumulative drug accumulation.

3. Indications

Remifentanil PCA should be considered when:

Neuraxial analgesia is contraindicated (coagulopathy, patient refusal, anatomical difficulty, previous spinal surgery, platelet count <80×10⁹/L)
Labour is too advanced for epidural placement
Accidental dural puncture has occurred with the epidural
Technical failure of epidural analgesia
Obstetric indications (e.g. breech, twin delivery, trial of labour after caesarean)
Patient preference after appropriate counselling

4. Dosing Protocol

Standard Regimen

Preparation: 1 mg remifentanil in 50 mL normal saline → concentration = 20 mcg/mL
Bolus dose: 20–40 mcg (1–2 mL)
Lock-out interval: 2 minutes (allows one bolus per contraction cycle)
Background infusion: Not recommended — significantly increases risk of respiratory depression
Starting dose: Lower end for nulliparas; slightly higher for multiparas

Dose Titration

Increase bolus incrementally (in 5–10 mcg steps) if:

Pain intensity remains unacceptable
Respiratory rate is >9 breaths/min
SpO₂ ≥ 94%
Heart rate >50 bpm
Sedation score ≤ 2 (patient awake/slightly drowsy)

Patient Instruction

Instruct the parturient to press the button at the very start of or just before a contraction, so peak drug effect coincides with peak pain.

5. Analgesic Efficacy

Provides superior analgesia to nitrous oxide (Entonox) and other parenteral opioids (pethidine, fentanyl)
Inferior to epidural analgesia — does not achieve complete pain elimination
Analgesic efficacy declines as labour progresses (pain intensity increases during transition and second stage)
Network meta-analysis (Wydall et al., Can J Anaesth 2023, PMID: 36720838) confirmed: remifentanil PCA is superior to fentanyl PCA for early analgesia but inferior to all epidural delivery modes
Meta-analysis (Lei et al., PLoS ONE 2022, PMID: 36534641) — 10 RCTs, 3086 parturients — found comparable maternal pain satisfaction between remifentanil PCA and epidural analgesia (SMD = 0.03, P = 0.90)

6. Maternal Side Effects

Respiratory Depression ⚠️ — Most Serious

Most significant risk — remifentanil PCA is associated with a significantly higher incidence of respiratory depression compared to epidural (OR = 3.56, 95% CI: 2.45–5.16; Lei et al. 2022)
Can cause apnoea, severe oxygen desaturation, and — rarely — cardiorespiratory arrest
Risk highest with background infusions and excessive bolus doses

Other Maternal Side Effects

Side Effect	Notes
Sedation	Commonest adverse effect; must be monitored continuously
Nausea/vomiting	Reported; less than with pethidine
Pruritus	Present but less than with intrathecal opioids
Dizziness	Related to peak plasma concentrations
Bradycardia	Uncommon but possible
Intrapartum fever	Less common than with epidural (OR = 0.43; Lei et al. 2022) — an advantage of remifentanil PCA

7. Fetal and Neonatal Effects

Remifentanil crosses the placenta rapidly due to its lipophilicity
However, it is rapidly metabolised in the fetal/neonatal circulation (ester hydrolysis)
Neonatal respiratory depression: generally mild and transient
Apgar scores <7 at 5 minutes: No significant difference between remifentanil PCA and epidural (OR = 1.18, P = 0.53; Lei et al. 2022)
Continuous CTG/fetal monitoring is mandatory during use
Remifentanil PCA should be discontinued when the patient is actively pushing in second stage to minimise neonatal exposure at delivery
Neonatal resuscitation equipment and naloxone must be immediately available

8. Monitoring Requirements

Remifentanil PCA demands rigorous, continuous monitoring — this is a prerequisite for safe use:

Parameter	Frequency
Sedation score	Continuous; goal: awake (Ramsay ≤2 or sedation score ≤2/5)
SpO₂ (pulse oximetry)	Continuous
Respiratory rate	Every 5 min (first 30 min), then every 15 min
Heart rate & blood pressure	Every 5 min initially, then every 30 min
End-tidal CO₂ (capnography)	Continuous (where available)
CTG (fetal heart rate)	Continuous
Level of consciousness	Continuous

A dedicated, continuous midwife presence is MANDATORY whenever remifentanil PCA is in use.

Supplemental Oxygen

Routine low-flow supplemental oxygen (2 L/min via nasal cannula) is used in many centres to provide a safety buffer, particularly at peak bolus effect.

9. Contraindications

Absolute	Relative
Patient refusal	Obesity / obstructive sleep apnoea
Known opioid allergy	Severe asthma
Parenteral opioid given within preceding 4 hours	Poor baseline oxygen saturation
Unable to operate PCA device	Lack of continuous one-to-one monitoring
Inability to consent

10. Comparison with Epidural Analgesia

Outcome	Remifentanil PCA	Epidural Analgesia
Analgesic efficacy	Moderate; inferior	Superior
Maternal satisfaction	Similar	Similar
Intrapartum fever	Less common ✓	More common
Respiratory depression	Higher risk ✗	Lower risk
Motor block	None ✓	Common
Hypotension	Rare	More common
Neonatal Apgar <7 at 5 min	Similar	Similar
One-to-one monitoring	Required	Not mandatory
Availability	Where epidural not possible ✓	Gold standard

11. Advantages

No motor block — parturient remains mobile
No risk of hypotension from sympathetic block
Self-administered — empowers parturient
Rapid reversibility — effect dissipates quickly if complications arise
Lower incidence of intrapartum fever compared to epidural
Can be combined with Entonox safely
Useful bridge while epidural is being sited

12. Disadvantages and Safety Concerns

Off-label use requiring informed consent
Inferior analgesia compared to epidural
High risk of maternal respiratory depression and apnoea
Mandates continuous one-to-one midwifery presence
Analgesic efficacy decreases as labour progresses
Cannot achieve complete pain elimination
Neonatal respiratory depression risk (though generally mild)
Requires rigorous monitoring infrastructure (SpO₂, capnography, sedation scoring)

13. Safety Framework: The RemiPCA SAFE Project

The international RemiPCA SAFE project advocates standardised auditing and reporting of remifentanil PCA use. Key recommendations:

No background infusion — bolus-only regime
Continuous one-to-one midwife presence
Continuous SpO₂ monitoring in all patients
Capnography where available
Regular sedation scoring
Clear escalation protocols for respiratory events
Resuscitation equipment immediately at bedside (bag-mask, naloxone)
Training and competency requirements for all staff involved

14. Practical Tips

Time the button press: teach patient to press at the very start of a contraction (not during peak)
Start conservative and titrate up — avoid overshooting
Stop PCA in second stage when actively pushing
If SpO₂ drops below 94% or sedation score ≥3: stop PCA, apply oxygen, stimulate patient, call for help
Naloxone (100–400 mcg IV) should be drawn up and immediately available
Document verbal consent in notes

15. Summary

Remifentanil PCA is a valuable, evidence-based second-line option for labour analgesia, particularly when epidural analgesia is contraindicated or unavailable. Its ultrashort pharmacokinetics provide a good fit for the cyclical pain of contractions. While comparable to epidural in terms of maternal satisfaction and neonatal outcomes, it carries a meaningfully higher risk of maternal respiratory depression and mandates continuous one-to-one monitoring. The bolus-only regimen (20–40 mcg, 2-min lockout, no background infusion) with meticulous vigilance is the safest approach.

Miller's Anesthesia, 10e: "For obstetric patients who are not candidates for epidural analgesia, remifentanil PCA may provide an alternative for analgesia in the peripartum period, but caution is warranted particularly regarding hypoxemia." — Miller's Anesthesia, 10e (Vol 2)

Key Point (Miller's): "Remifentanil patient-controlled analgesia (PCA) offers superior pain relief to nitrous oxide and less fetal effects than other intravenous opioid analgesics, but its analgesic effects are inferior to epidural analgesia, and it requires careful maternal oxygenation and ventilation monitoring."

Key References:

Lei X et al. PLoS One 2022. PMID 36534641 — Meta-analysis (10 RCTs, 3086 patients): remifentanil PCA vs epidural
Wydall S et al. Can J Anaesth 2023. PMID 36720838 — Network meta-analysis comparing all labour analgesia modalities
Rone I, Weinger CF. BJA Education 2019 — Non-regional analgesia for labour: remifentanil in obstetrics
Jelting Y et al. Anaesthesia 2017 — Cochrane systematic review: remifentanil PCA vs parenteral alternatives
Miller's Anesthesia, 10e, Chapter 58 — Obstetric Anaesthesia
Barash Clinical Anaesthesia, 9e, Chapter on Obstetric Anaesthesia

This is a shared conversation. Sign in to Orris to start your own chat.